OncoSil Medical Ltd (ASX: OSL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
OncoSil Medical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$16.29 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
23.62 million
Earnings per share
-1.374
Dividend per share
N/A
Year To Date Return
-25.35%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
OncoSil Medical Ltd (ASX: OSL)
Latest News
Healthcare Shares
The OncoSil Medical share price is booming 66%. Here's why
Healthcare Shares
Why is the OncoSil Medical (ASX:OSL) share price surging 18% today?
Healthcare Shares
Why the OncoSil (ASX:OSL) share price finished the day higher today
Share Market News
Here's why the OncoSil Medical (ASX:OSL) share price has jumped 10% today
OSL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About OncoSil Medical Ltd
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
OSL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 11 Feb 2026 | $0.70 | $-0.02 | -2.78% | 883,019 | $0.72 | $0.75 | $0.70 |
| 10 Feb 2026 | $0.72 | $0.04 | 5.88% | 192,958 | $0.70 | $0.73 | $0.66 |
| 09 Feb 2026 | $0.68 | $0.00 | 0.00% | 164,553 | $0.69 | $0.70 | $0.66 |
| 06 Feb 2026 | $0.68 | $-0.04 | -5.56% | 116,561 | $0.72 | $0.72 | $0.67 |
| 05 Feb 2026 | $0.72 | $0.01 | 1.42% | 307,005 | $0.74 | $0.74 | $0.70 |
| 04 Feb 2026 | $0.71 | $0.01 | 1.44% | 156,683 | $0.72 | $0.80 | $0.70 |
| 03 Feb 2026 | $0.70 | $-0.10 | -12.57% | 232,269 | $0.80 | $0.80 | $0.69 |
| 29 Jan 2026 | $0.80 | $-0.03 | -3.64% | 50,919 | $0.81 | $0.81 | $0.77 |
| 28 Jan 2026 | $0.83 | $-0.01 | -1.20% | 10,928 | $0.85 | $0.85 | $0.83 |
| 27 Jan 2026 | $0.84 | $0.08 | 10.59% | 93,921 | $0.77 | $0.89 | $0.77 |
| 23 Jan 2026 | $0.76 | $-0.02 | -2.56% | 31,847 | $0.79 | $0.79 | $0.76 |
| 22 Jan 2026 | $0.78 | $-0.06 | -7.14% | 107,007 | $0.85 | $0.85 | $0.78 |
| 21 Jan 2026 | $0.84 | $-0.06 | -6.63% | 27,716 | $0.89 | $0.89 | $0.84 |
| 20 Jan 2026 | $0.90 | $-0.01 | -1.09% | 2,920 | $0.90 | $0.90 | $0.90 |
| 19 Jan 2026 | $0.91 | $0.00 | 0.00% | 13,632 | $0.92 | $0.92 | $0.91 |
| 16 Jan 2026 | $0.92 | $0.00 | 0.00% | 10,710 | $0.92 | $0.92 | $0.91 |
| 15 Jan 2026 | $0.91 | $0.01 | 1.11% | 2,992 | $0.92 | $0.92 | $0.91 |
| 14 Jan 2026 | $0.90 | $0.05 | 5.85% | 3,810 | $0.89 | $0.90 | $0.89 |
| 13 Jan 2026 | $0.86 | $-0.01 | -1.16% | 39,641 | $0.87 | $0.87 | $0.84 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 01 Dec 2025 | Nigel Lange | Issued | 114,157 | $126,999 |
Director remuneration. As per announcement
|
| 01 Dec 2025 | Thomas (Tom) Duthy | Issued | 41,067 | $45,687 |
Director remuneration.
|
| 01 Dec 2025 | Thomas (Tom) Duthy | Issued | 172,811 | $192,252 |
Director remuneration.
|
| 01 Dec 2025 | Lelde Smits | Issued | 41,067 | $45,687 |
Director remuneration.
|
| 19 Jun 2025 | Lelde Smits | Issued | 7,500 | $90,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Peter James MacDonald Hall | Non-Executive Director | Oct 2024 |
Mr Hall is a London-based Australian financier, media proprietor and philanthropist. He founded investment firm Hunter Hall Investment Management in 1993, and acted as Chief Investment Officer and Executive Chairman during his 23 year tenure.
|
| Mr Nigel Lange | Chief Executive OfficerManaging Director | Jan 2021 |
Mr Lange has 31 years of experience in the medical devices industry. Since 2003, he has held various leadership roles with Sirtex Medical, a global leader in brachytherapy treatment for liver cancer. From 2003, he served as Chief Executive Officer of Sirtex's European business. Since 2017, he served as Group Chief Commercial Officer. During this time, he has also held interim roles including Interim Group CEO and Interim CEO of Asia Pacific. He is also a member of Risk Committee.
|
| Dr Thomas (Tom) Duthy | Non-Executive Director | Jul 2025 |
Dr Duthy brings more than 21 years of experience across financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. He was previously Head of Corporate Development and Investor Relations at Sirtex Medical (ASX:SRX). Dr Duthy is the Founder and Director of Nemean Group, a corporate advisory firm serving healthcare and technology companies, and has been involved in M&A transactions. He currently advises Mayne Pharma (ASX:MYX) and serves as a Non-Executive Director of Invex Therapeutics (ASX:IXC).
|
| Ms Lelde Smits | Non-Executive Director | Jan 2025 |
Ms Smits has global financial markets experience through producing and presenting thousands of finance reports and CEO interviews as a broadcast finance journalist in Australia and as a New York foreign correspondent for the Australian Financial Review, reporting from Wall Street, U.S.A. Lel is currently a Director of Australian Shareholders' Association. She is also a member of Risk Committee.
|
| Mr Tim Luscombe | Joint Company Secretary |
-
|
|
| Mr Douglas Cubbin | Chairman |
-
|
|
| Tim Luscombe | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| BNP Paribas Noms Pty Ltd | 3,468,217 | 18.42% |
| HSBC Custody Nominees (Australia) Limited | 1,567,748 | 8.33% |
| Citicorp Nominees Pty Limited | 1,287,021 | 6.84% |
| Mrs Sarah Cameron | 647,358 | 3.44% |
| Warbont Nominees Pty Ltd (Unpaid Entrepot A/C) | 396,483 | 2.11% |
| Neweconomy Com Au Nominees Pty Ltd (900 Account) | 356,848 | 1.90% |
| Bannaby Investments Pty Limited (Bannaby Super Fund A/C) | 245,000 | 1.30% |
| Webinvest Pty Ltd (OLSB Unit A/C) | 240,000 | 1.27% |
| MyConsulting Pty Ltd | 240,000 | 1.27% |
| Alua Capital Pty Ltd | 206,250 | 1.10% |
| Newfound Investments Pty Ltd (Newfound Superannuation A/C) | 200,000 | 1.06% |
| Finclear Services Pty Ltd (Superhero Securities A/C) | 160,476 | 0.85% |
| Peter Kyros Pty Ltd (Kyros SF A/C) | 151,642 | 0.81% |
| Jamplat Pty Ltd | 150,000 | 0.80% |
| Tisia Nominees Pty Ltd (Henderson Family A/C) | 135,024 | 0.72% |
| BNP Paribas Nominees Pty Ltd (IB AU Noms RetailClient) | 132,979 | 0.71% |
| Mrs Lindy Anna Frohnert | 125,586 | 0.67% |
| JP Morgan Nominees Australia Pty Ltd | 121,699 | 0.65% |
| Mr Peter Barrett Capp (Capp Family A/C) | 100,000 | 0.53% |
| Structure Investments Pty Ltd (Rogers Family A/C) | 100,000 | 0.53% |
